Benefits Of Anti-Clotting Drug Class For People With Acute Coronary Syndromes - But For Men Only? (p 189)January 17, 2002Results of a meta-analysis in this week's issue of THE LANCET lend further support to the benefits of the anti-clotting drugs glycoprotein IIb/IIIa inhibitors for the treatment of patients with acute coronary syndromes. However, an unexpected finding of the study suggests that men might be more likely to benefit from therapy with this class of drugs. Platelet glycoprotein IIb/IIIa inhibitors are a class of drugs which prevent blood clotting in the coronary arteries; they have been shown to reduce cardiac complications in patients undergoing percutaneous coronary intervention (PCI; balloon angioplasty or coronary stenting). However, The value of these drugs in patients with acute coronary syndromes who did not have PCI is uncertain. Eric Boersma from University Hospital Rotterdam, The Netherlands, and colleagues pooled data from six previously published trials which involved a total of around 31,400 patients from 41 countries. 30 days after randomisation, 3530 (11%) of patients died or had a myocardial infarction (heart attack). Patients randomised to receive a glycoprotein IIb/IIIa inhibitor were 9% less likely to die or to have a myocardial infarction compared with patients given placebo or control medication. Unexpectedly, men given glycoprotein IIb/IIIa inhibitors had a 19% reduction in the risk of death or myocardial infarction within 30 days compared with placebo or control; by contrast, treatment effect was compatible with a 15% risk increase among women. The relative treatment benefit was similar in subgroups of patients according to important clinical baseline characteristics-the absolute treatment benefit was therefore largest in high-risk patients. Major bleeding complications were slightly increased in patients given glycoprotein IIb/IIIa inhibitors (2.4% compared with 1.4%). Eric Boersma comments: "Glycoprotein IIb/IIIa inhibitors reduce the occurrence of death or myocardial infarction in patients with acute coronary syndromes not routinely scheduled for early revascularisation. The event reduction is greatest in patients at high risk of thrombotic complications. Treatment with a glycoprotein IIb/IIIa inhibitor might therefore be considered especially in such patients early after admission, and continued until a decision about early coronary revascularisation has been made." Lancet |
|||||||||||||||||||||
Science Research Departments
Earth Science Alternative Energy | Anthropology and Archaeology | Earthquakes and Volcanoes | Environment and Nature News | Global Warming | High-Energy and Particle Physics | Ozone Hole | Scientists Slow Light | Tsunami Space Science Astronomy and Space News | Black Holes | Chandra X-Ray Observatory | Extrasolar Planets | Hubble Telescope | International Space Station | Jupiter Galileo Mission | Jupiter Cassini Mission Flyby | Mars Exploration | Mars Odyssey 2001 | Mars Global Surveyor | Mars Polar Lander | Mars Climate Orbiter | Mars Pathfinder | Meteors and Asteroids | Mir Space Station | NEAR Asteroid Probe Mission | Pluto Planet Debate | Search for Extraterrestrial Life | Space Shuttle Program | Space Shuttle Mission: STS-102 | Space Weather Life Science Animal News | Biotechnology and Genetics | Brain Research | Human Cloning | Dinosaur and Fossil Discoveries | Endangered Species | Gene Therapy | Genetically Modified Food | Stem Cell Research | Whales and Whaling |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||